ArticleThe Journal of biological chemistry2014
Carbohydrate sequence of the prostate cancer-associated antigen F77 assigned by a mucin O-glycome designer array.
Article in The Journal of biological chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 52 citations in OpenAlex.
- F77 antigen is a promising target for adoptive T cell therapy of prostate cancer.Biochemical and biophysical research communications · 2023Article
- CD44 Glycosylation as a Therapeutic Target in Oncology.Frontiers in oncology · 2022Review
- Metabolic precision labeling enables selective probing of O-linkedProceedings of the National Academy of Sciences of the United States of America · 2020Article
- An Integrated Workflow for Global, Glyco-, and Phospho-proteomic Analysis of Tumor Tissues.Analytical chemistry · 2020Article
- Glycan Markers of Human Stem Cells Assigned with Beam Search Arrays.Molecular & cellular proteomics : MCP · 2019Article
- Glycan Microarrays as Chemical Tools for Identifying Glycan Recognition by Immune Proteins.Frontiers in chemistry · 2019Review
- A spliced form of CD44 expresses the unique glycan that is recognized by the prostate cancer specific antibody F77.Oncotarget · 2018Article
- O-Glycome Beam Search Arrays for Carbohydrate Ligand Discovery.Molecular & cellular proteomics : MCP · 2018Article
- Liquid Biopsy in the OMICS Era of Tumor Medicine.Open access journal of biomedical engineering and its applications · 2018Article
- Shotgun Glycomics Identifies Tumor-Associated Glycan Ligands Bound by an Ovarian Carcinoma-Specific Monoclonal Antibody.Scientific reports · 2017Article
- Characterization of H type 1 and type 1The Journal of biological chemistry · 2017Article
- The minimum information required for a glycomics experiment (MIRAGE) project: improving the standards for reporting glycan microarray-based data.Glycobiology · 2017Article
- Binding of CLL subset 4 B-cell receptor immunoglobulins to viable human memory B lymphocytes requires a distinctive IGKV somatic mutation.Molecular medicine (Cambridge, Mass.) · 2017Article
- Glycan Markers as Potential Immunological Targets in Circulating Tumor Cells.Advances in experimental medicine and biology · 2017Review
- Unraveling Sugar Chain Signatures of the "Seeds" of Tumor Metastasis.Journal of proteomics & bioinformatics · 2017Article
- Glycan Specificity of P[19] Rotavirus and Comparison with Those of Related P Genotypes.Journal of virology · 2016Article
- Generation and characterization of β1,2-gluco-oligosaccharide probes from Brucella abortus cyclic β-glucan and their recognition by C-type lectins of the immune system.Glycobiology · 2016Article
- The role of glycans in the development and progression of prostate cancer.Nature reviews. Urology · 2016Review
- I-branching N-acetylglucosaminyltransferase regulates prostate cancer invasiveness by enhancing α5β1 integrin signaling.Cancer science · 2016Article
- Glycoarray Technologies: Deciphering Interactions from Proteins to Live Cell Responses.Microarrays (Basel, Switzerland) · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 7 institutions in 3 countries.
Funding
Abstract
Monoclonal antibody F77 was previously raised against human prostate cancer cells and has been shown to recognize a carbohydrate antigen, but the carbohydrate sequence of the antigen was elusive. Here, we make multifaceted approaches to characterize F77 antigen, including binding analyses with the glycolipid extract of the prostate cancer cell line PC3, microarrays with sequence-defined glycan probes, and designer arrays from the O-glycome of an antigen-positive mucin, in conjunction with mass spectrometry. Our results reveal F77 antigen to be expressed on blood group H on a 6-linked branch of a poly-N-acetyllactosamine backbone. We show that mAb F77 can also bind to blood group A and B analogs but with lower intensities. We propose that the close association of F77 antigen with prostate cancers is a consequence of increased blood group H expression together with up-regulated branching enzymes. This is in contrast to other epithelial cancers that have up-regulated branching enzymes but diminished expression of H antigen. With knowledge of the structure and prevalence of F77 antigen in prostate cancer, the way is open to explore rationally its application as a biomarker to detect F77-positive circulating prostate cancer-derived glycoproteins and tumor cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.